Puma Biotechnology opened at $8.08, in line with its previous close of $8.08. In the last trading session, the stock traded between $8.08 and $8.25. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Puma Biotechnology is now worth
$ 231.11
Giving a profit of
$ 131.11 (131.11%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
+$0.01 (+0.11%)
Day High
$8.25
Day Low
$8.08
Day Open
$8.08
Prev Close
$8.08
Volume
3,62,645
1W Return
-24.33%
1M Return
-21.50%
3M Return
-7.95%
6M Return
13.29%
1Y Return
55.86%
Market Cap ($ Mn)
418
PE Ratio
17.77
PB Ratio
3.34
PEG Ratio
0.26
ROE
28.83%
ROCE
32.06%
EPS (TTM)
$0.12
1 Week
-24.33%
1 Month
-21.50%
3 Months
-7.95%
6 Months
13.29%
9 Months
21.82%
Puma Biotechnology grants inducement RSUs to three new employees
Puma Biotechnology granted inducement RSUs covering 18,500 shares to three new non-executive employees on November 2, 2026. The awards were issued under the 2017 Employment Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over a three-year period starting from a vesting commencement date of November 1, 2026.
8 days agoPuma Biotechnology grants 7,500 inducement RSUs to new employee
Puma Biotechnology granted 7,500 inducement RSUs to a new non-executive employee. The award was approved by the Compensation Committee on October 1, 2026. Vesting occurs over three years with one-third vesting on the first anniversary. The grant complies with Nasdaq Listing Rule 5635(c)(4) for inducement awards.
1mo agoPuma Biotechnology initiates Phase II alisertib trial for advanced small cell lung cancer
Puma Biotechnology initiates ALISCA-Lung2 Phase II trial for advanced small cell lung cancer. Trial evaluates alisertib combined with paclitaxel in approximately 50 patients. Primary endpoint is safety; secondary includes response rates and survival metrics. Company aims to identify biomarkers to guide future alisertib development. New trial complements existing ALISCA-Lung1 and ALISCA-Breast1 programs.
1mo agoPuma Biotechnology CEO to present at Wainwright conference on September 14
Alan H. Auerbach will present at the H.C. Wainwright conference on September 14, 2026. The event takes place at the Lotte New York Palace Hotel in New York City. Live webcast and slides will be available on the company website. Puma focuses on NERLYNX and alisertib for various cancer treatments.
2mo agoPuma Biotechnology grants 33,550 RSUs to five new employees
Puma Biotechnology granted 33,550 restricted stock units to five new non-executive employees. Awards vest over three years starting September 1, 2026, under the 2017 Inducement Plan. Grants comply with Nasdaq Listing Rule 5635(c)(4) as material employment inducements. Company continues clinical trials for alisertib in lung and breast cancer indications.
2mo agoPuma Biotechnology raises FY26 sales guidance to $231M high
Puma Biotechnology raises FY2026 sales guidance to $224.000M-$231.000M, beating the $222.000M estimate. The revision lifts both the floor and ceiling of the previous outlook, suggesting strong commercial momentum.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Puma Biotechnology is now worth
$ 231.11
Giving a profit of
$ 131.11 (131.11%)
Note: Past profits do not guarantee future returns.
